Hepatocellular Carcinoma parsian pharmaceutical co

Advances of Targeted Therapy for Hepatocellular Carcinoma

In the past decade, targeted therapy had made a ground-breaking progress in advanced Hepatocellular Carcinoma (HCC).

Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) Global Day

Annually the International ALS/MND Associations celebrates 21 June as the global day of recognition of ALS/MND, a disease that affects people in every country of the world.

Hepatocellular carcinoma

Hepatocellular carcinoma 

Liver cancer is a global health challenge, with an estimated incidence of >1 million patients by 2025. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.

Mantle Cell Lymphoma

Recent Results Show ibrutinib-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma

The combination of once-daily oral ibrutinib plus bendamustine-rituximab (BR) and rituximab maintenance significantly decreased the risk of disease progression or death by 25%

World MS Day

World MS Day

World MS Day is officially marked on 30 May. World MS Day is the MS movement’s annual campaign to raise awareness of the condition

MONKEYPOX

Monkeypox

The aim of this Disease Outbreak News is to raise public awareness, inform readiness and response efforts, and provide technical guidance for immediate actions.

thyroid cancer

Targeted therapies used in the Treatment of Thyroid Cancer

Newer medicines that specifically target the changes inside cells, which cause them to become cancerous, are now being used to treat some thyroid cancers.

Autoimmune

World AUTO immune & AUTO inflammatory Arthritis Day 

There is no other globally program focused on Autoimmune Arthritis and associated diseases that is as big as World Autoimmune Arthritis Day.

The Clinical Efficacy of Combinatorial Therapy of EGFR-TKI and Crizotinib in Overcoming MET amplification-mediated Resistance

Recent studies have support the efficacy of combinatorial regimen with either first- or third-generation EGFR-TKI and crizotinib after the emergence of MET amplification-mediated EGFR-TKI resistance in patients with EGFR-mutant NSCLC.

Crizotinib

Benefits of Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-small-cell lung cancer has poor prognosis and low survival rates, providing a strong rationale for the development of new treatment strategies.

Melonama

It is Good to Know about the Dark Side of the Sun

Skin cancer, including melanoma as well basal and squamous cell carcinomas, is the most common cancer type.

Lenalidomide

Benefits of lenalidomide in hematological malignancies

Lenalidomide is an immunomodulatory drug, which has effect against most of the hematological malignancies.

Risk of Developing Diabetes

COVID-19 infection even mild ones may increase Risk of Developing Diabetes 

People who get COVID-19 have a greater risk of developing diabetes up to a year later, even after a mild SARS-CoV-2 infection…

JAK inhibitor

An overview of Tofacitinib, the first FDA approved JAK inhibitor, and its Indications

Tofacitinib works inside the cell to inhibit inflammation by blocking JAK-dependent signaling pathways and production of many inflammatory cytokines.

JAK inhibitors

JAK inhibitors As a New Therapeutic Option

The JAK/STAT signaling pathway is an universally expressed intracellular signal transduction pathway; involved in many crucial biological roles,

Direct Factor Xa inhibitors

Benefits of Direct Factor Xa inhibitors over Warfarin

Compared to vitamin K antagonists (VKAs), these target-specific drugs have a fixed dosing with no need for international normalized ratio (INR) monitoring

Direct Factor Xa inhibitors

Role of Direct Factor Xa inhibitors in Cardiovascular Events

Direct Factor Xa inhibitors work by selectively and reversibly blocking the activity of clotting factor Xa, preventing clot formation.

Molnupiravir

WHO Backs Molnupiravir for High-Risk Covid-19 Patients

The ninth update of WHO’s guideline on COVID-19 therapeutics includes a conditional recommendation on molnupiravir, a new antiviral medicine.

Amyotrophic lateral sclerosis (ALS)

Review over Amyotrophic Lateral Sclerosis (ALS) and the First FDA-Approved Drug for Treatment of ALS:

Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disease that affects nerve cells which control voluntary muscle movement.

Empagliflozin

The U.S. FDA Approved Empagliflozin for Wider Range of Patients with Heart Failure

Heart failure represents a significant, growing disease burden in the U.S., with more than 8 million cases expected by 2030.

Type 2 Diabetes Mellitus

Role of SGLT2 and DPP-4 Inhibitors in the treatment of Type 2 Diabetes Mellitus

Type 2 diabetes mellitus is the most common type of diabetes, in which the blood glucose, is too high.

DISEASE-MODIFYING THERAPIES (DMTs)

Quick Review Over Disease Modifying Therapies (DMTs) For Multiple Sclerosis

Multiple sclerosis (MS) is a lifelong, and often disabling disease which affects the central nervous system. In multiple sclerosis, scattered patches of the protective….

Multiple sclerosis (MS)

Quick Review over Multiple sclerosis (MS)

Multiple sclerosis (MS) is a lifelong, and often disabling disease which affects the central nervous system. In multiple sclerosis, scattered patches of the protective….

Graft-versus-Host Disease (GvHD) parsian pharmaceutical co

Quick Review over Graft-versus-Host Disease (GvHD)

GvHD is a complication because of a transplantation using donor; when the donor’s immune system recognizes the patient’s organs as unfamiliar, which should be destroyed.

Waldenström Macroglobulinemia (WM)

Quick overview of WaldenstrOm Macroglobulinemia (WM)

Waldenstrom macroglobulinemia (WM) is a non-Hodgkin lymphoma (NHL), in which the cancer cells make large amounts of an abnormal protein (called a macroglobulin).

Marginal Zone Lymphoma (MZL)

Quick overview of Marginal Zone Lymphoma (MZL):

Marginal zone lymphoma (MZL) is a group of B-cell non-Hodgkin lymphomas which at first is formed in certain areas (the marginal zones) of lymph tissue.

Mantle cell lymphoma (MCL)

Mantle cell lymphoma (MCL)

Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma (NHL).

Small Lymphocytic Lymphoma(SLL)

Small Lymphocytic Lymphoma (SLL)

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are cancers of the immune system; which affect lymphocytes.

Chronic lymphocytic leukemia (CLL)

Chronic lymphocytic leukemia which is also called CLL is a cancer of the blood and bone marrow which usually is  worsen slowly…

chronic myeloid leukemia (CML)

chronic myeloid leukemia (CML)

Chronic myeloid leukemia (CML) is an uncommon form of the bone marrow cancer.

acute lymphocytic leukemia (ALL)

acute lymphocytic leukemia (ALL)

Leukemia is a cancer of the blood-forming tissues, like the lymphatic system and the bone marrow.

leukemia

A quick review over Leukemia

Leukemia is a cancer of the blood-forming tissues, like the lymphatic system and the bone marrow.

Some tips for patients who are taking a CDK4/6 inhibitor

Some tips for patients who are taking a CDK4/6 inhibitor

If you are taking a CDK4/6 inhibitor, in this article Parsian pharma have collected some recommendations that can help things go more easily…

aromatase inhibitors

Parsian pharma review of aromatase inhibitors citing to the recent articles regard this subject:

Letrozole seems to be the best choice for the most breast cancer patients whenever a non-steroidal aromatase inhibitor has to be chosen in a clinical setting.

FDA panel of advisory narrowly endorses Merck’s at-home Covid-19 treatment pill, despite reduced efficacy and safety questions…. .

U.S FDA panel of advisory narrowly endorses Merck’s at-home Covid-19 treatment pill

 

CDK46 inhibitors

Parsian pharama review of CDK4/6 inhibitors citing to the recent articles

CDK4/6 inhibitors, the newest class of interest for advanced breast cancer ….

 

Cancer

Cancer Statistics, 2021

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence.

Protein Tyrosine Kinases

Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia

Protein kinases constitute a large group of enzymes catalysing protein phosphorylation and controlling multiple signalling events. Over the last 30 years, a major focus of research has been directed towards cancer-associated tyrosine kinases owing to their critical contributions to the development and aggressiveness of human malignancies through the pathological effects on cell behaviour.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors inhibit tumor cells, and can be used as a treatment for non-small cell lung cancer…